CPN-219, a next-generation hexapeptidic NMUR2 agonist, achieves a dose-dependent and selective activation of NMUR2 with an EC50 value of 2.2 nM[1].
in vivo
CPN-219 (25-250 μg; intranasal administration) suppresses body weight gain of mice in a dose-dependent manner. In contrast, intraperitoneal injection (250 μg) is ineffective[1].
Animal Model:
ddY mice[1].
Dosage:
250, 100, 25 μg/mouse.
Administration:
Applied to the nasal cavity; at days 1 and 4
Result:
Suppressed body weight gain of mice in a dose-dependent manner.
IC 50
NMUR2
References
[1] Kentaro Takayama, et al. A chemically stable peptide agonist to neuromedin U receptor type 2. Bioorg Med Chem. 2020 May 15;28(10):115454. DOI:10.1016/j.bmc.2020.115454
